Article: Acorda Therapeutics Announces Initiation of AMPYRA® Proof-of-Concept Study in Patients with Post-Stroke Deficits

I wanted to let you know about a clinical trial for an investigational medication called dalfampridine (Ampyra), for people who are suffering from chronic problems with motor skills more than six months after an ischemic stroke. This study is still recruiting participants at many location in the US.

More details about the study, including sites involved in the research, can be found at: http://clinicaltrials.gov/show/NCT01605825

From the press release "Acorda Therapeutics Announces Initiation of AMPYRA® Proof-of-Concept Study in Patients with Post-Stroke Deficits".

"This proof-of-concept study will assess the safety and tolerability of AMPYRA in people with stable post-stroke deficits after an ischemic stroke. Exploratory efficacy outcome measures will include: changes in walking speed, upper and lower extremity motor and sensory function, manual dexterity, assessment of functional independence in performing activities of daily living, and clinician and subject global impressions of general improvement. The study is expected to include approximately 66 people who have experienced an ischemic stroke at least six months prior to enrollment, by which time the deficits are generally stable. The Company expects to announce initial study results in early 2013. "